These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3660472)

  • 1. The role of combination cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy in advanced non-small-cell lung cancer.
    Rosell Costa R; Abad-Esteve A; Roig Cutilles J; Solorzano IM; Fernandez Marcial C; Ribas Mundo M
    Tumori; 1987 Aug; 73(4):345-9. PubMed ID: 3660472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.
    Feld R; Rubinstein L; Thomas PA
    J Natl Cancer Inst; 1993 Feb; 85(4):299-306. PubMed ID: 8381187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
    Kolarić K; Roth A; Vukas D; Cervek J
    Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.
    Davis S; Rambotti P; Park YK
    Cancer Treat Rep; 1981; 65(11-12):955-8. PubMed ID: 7028257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer.
    Colozza M; Gori S; Mosconi AM; Belsanti V; Basurto C; Rossetti R; Di Costanzo F; Buzzi F; Bacchi M; Davis S
    Am J Clin Oncol; 1989 Apr; 12(2):137-41. PubMed ID: 2705403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial.
    Feld R; Rubinstein L; Thomas PA
    Chest; 1994 Dec; 106(6 Suppl):307S-309S. PubMed ID: 7988250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.
    Britell JC; Eagan RT; Ingle JN; Creagen ET; Rubin J; Frytak S
    Cancer Treat Rep; 1978 Aug; 62(8):1207-10. PubMed ID: 688256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
    Tzekova V; Velikova M; Koynov K; Micheva D; Donchev T
    Neoplasma; 1991; 38(6):603-7. PubMed ID: 1766485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer.
    Creagan ET; Green SJ; Ahmann DL; Ingle JN; Edmonson JH; Marschke RF
    J Clin Oncol; 1984 Nov; 2(11):1260-5. PubMed ID: 6387059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
    Veronesi A; Magri MD; Tirelli U; Carbone A; Mazza F; Franceschi S; Talamini R; Ardizzoni A; Canobbio L; Rosso R
    Am J Clin Oncol; 1988 Oct; 11(5):566-71. PubMed ID: 2845769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
    Cleri LB; Kris MG; Tyson LB; Pisters KM; Clark RA; Gralla RJ
    Cancer; 1995 Sep; 76(5):774-8. PubMed ID: 8625179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K; Vukas D; Potrebica V
    Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.